Key result
Phosphocreatine evaluated for impact on anticancer therapy completion in patients at risk of cardiotoxicity.
Why the study?
Cardiovascular morbidity, including heart failure from anticancer drug cardiotoxicity, is a leading cause of death in cancer survivors, making cardioprotective strategies critical.
Observational (n=200)
Yes
May support cardioprotective strategies in cancer survivors; leaves open need for randomized confirmation.
Enhanced cancer treatment efficacy has resulted in a significant increase in the number of cancer survivors after the cure of malignant tumors. However, cardiovascular morbidity, including chronic heart failure, has become the leading cause of death and decreased life expectancy among cancer survivors. This is due, in particular, to the cardiotoxic effects of anticancer drugs and associated factors. Cardioprotective approaches aim to reduce the incidence and severity of cardiotoxicity through the use of cardioprotective agents (e.g., dexrazoxane), liposomal drug delivery systems (e.g., liposomal doxorubicin), and optimization of drug administration schedules. Reducing the cardiotoxicity of cancer treatments is a clinically important goal. Phosphocreatine-based therapy represents a potentially valuable new strategy in this area. In this regard, the study "Multicenter prospective observational study to investigate the experience of using phosphocreatine in combination therapy for heart failure caused by cancer treatment" was initiated. This publication presents the protocol of the observational non-interventional NEOCARD study.
No takes yet. Share an insight, caveat, or question.
Сафиуллина et al. (2025) conducted an observational in Heart failure caused by cancer treatment (cardiotoxicity) (n=200). Phosphocreatine was evaluated on Frequency of completion of anticancer therapy according to the prescribed regimen. The NEOKARD study is a prospective observational study designed to evaluate the effect of phosphocreatine on the completion rate of anticancer therapy in 200 patients at risk of cardiotoxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: